Canaccord Genuity cuts Structure Therapeutics target price to $107 from $111
GPCR•Canaccord Genuity cut its target price for Structure Therapeutics to $107 from $111.
Related News
Raymond James cuts Ionis Pharmaceuticals target price to $54 from $79
IONS•
Qualys, Inc.: Baird raises target price to $210 from $160
QLYS•
Philip Morris: JPMorgan reinstates coverage with neutral rating; target price $200
PM•
What we know about Megaspeed, Singapore-based customer of Nvidia
NVDA•
North Sea gas maintenance schedule adds St. Fergus outage
UNG•